|
INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing to Phase II Trials
|
17 Dec, 2019 |
|
INmune Bio, Inc. Announces First Alzheimer’s Disease Patient Dosed in XPro1595 Study
|
02 Dec, 2019 |
|
INmune Bio Inc. to Discuss Potential New Alzheimer’s Disease Treatments in CTAD Pre-Conference Webinar
|
26 Nov, 2019 |
|
INmune Bio, Inc. Strengthens Board of Directors with Appointment of Veteran Finance Executive Marcia Allen
|
19 Nov, 2019 |
|
INmune Bio, Inc. Reports Third Quarter 2019 Financial Results and Provides Shareholder Update
|
08 Nov, 2019 |
|
INmune Bio, Inc. Announces Potentially Strong Link Between Obesity and Alzheimer's Disease at the Society for Neuroscience 49th Annual Meeting
|
21 Oct, 2019 |
|
INmune Bio, Inc. Announces Presentation of Data Related to its Lead Compound XPro1595 at the Society for Neuroscience’s Annual Meeting
|
17 Oct, 2019 |
|
INmune Bio Inc. to Present at Advances in Immuno-Oncology USA Congress and at World Immunotherapy Congress in October
|
08 Oct, 2019 |
|
CEO of INmune Bio Inc. Discusses Company Accomplishments at Nasdaq’s MarketSite and Announces Presentation at World Immunotherapy Congress
|
24 Sep, 2019 |
|
INmune Bio to Present XPro1595 for Treating Neuroinflammation in Alzheimer’s Disease at 2019 Alzheimer’s Association International Conference (AAIC) Satellite Symposium
|
23 Sep, 2019 |
|
INmune Bio Invited to Speak on Company’s Advancements in Cancer Treatments at the Targeting Innate Immunity Congress and MarketsandMarkets Next Gen Immuno-Oncology Congress
|
17 Sep, 2019 |
|
INmune Bio Inc. Announces USPTO Allowance of Key Patent Covering Its DN-TNFa Platform Technology for Treating Cancer
|
12 Sep, 2019 |
|
INmune Bio to Present at the H.C. Wainwright 21st Annual Healthcare Conference on Tuesday, September 10th at 2:10 p.m. ET
|
05 Sep, 2019 |
|
INmune Bio Inc. to Introduce NeuLiv™ Program for Treatment of NASH at H.C. Wainwright 21st Annual Global Investment Conference
|
04 Sep, 2019 |
|
INmune Bio Reports Second Quarter 2019 Financial Results and Provides Shareholder Update
|
12 Aug, 2019 |
|
INmune Bio Appoints Biotechnology Executive Edgardo Baracchini as New Board Member
|
08 Aug, 2019 |
|
INmune Bio Reports Positive Preliminary Data from INB03 Phase I Clinical Trial in Cancer
|
05 Aug, 2019 |
|
INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit
|
01 Aug, 2019 |
|
INmune Bio Co-Founder and CEO Presents at 17th Annual Congress of International Drug Discovery Science & Technology 2019
|
25 Jul, 2019 |
|
INmune Bio Co-Founder and CEO Presents at Maxim Group’s Conference on Alzheimer’s Disease
|
03 Jul, 2019 |
|
INmune Bio Announces Publication of Data on INKmune Primed NK cells in Peer-Reviewed Journal PLOS ONE
|
27 Jun, 2019 |
|
INmune Bio to present Alzheimer’s Drug Candidate XPro1595 at The TNF Conference
|
04 Jun, 2019 |
|
INmune Bio to Present at the 9th Annual LD Micro Invitational on June 5th
|
28 May, 2019 |
|
INmune Bio Announces Common Stock Purchase Agreement for up to $20.0 Million with Lincoln Park Capital
|
16 May, 2019 |
|
INmune Bio Reports First Quarter 2019 Financial Results and Provides Shareholder Update
|
15 May, 2019 |
|
INmune Bio Closes Private Placement of Approximately $4.1 Million of Common Stock, Led by Insiders and Existing Shareholders
|
07 May, 2019 |
|
INmune Bio Presenting Poster at the Neuroimmunology Drug Development Summit
|
17 Apr, 2019 |
|
INmune Bio Co-Founder and CEO to Speak at Cambridge Healthtech Institute’s 10th Annual Inflammation Inhibitors Conference
|
09 Apr, 2019 |
|
INmune Bio Announces Poster Presentation with New Data Regarding Neurodegenerative Disease Drug Candidate, XPro1595, at The European Conference on Neuroinflammation
|
08 Apr, 2019 |
|
INmune Bio to Ring the NASDAQ Closing Bell on Tuesday, April 9, 2019
|
02 Apr, 2019 |
|
INmune Bio Co-Founder and CEO Presented at Cambridge Healthtech Institute’s 4th Annual Immuno-Oncology Summit Europe 2019
|
19 Mar, 2019 |
|
INmune Bio Co-Founders to Present at World Immunotherapy Congress during the Festival of Biologics San Diego
|
26 Feb, 2019 |
|
INmune Bio Awarded a $1 Million Grant for the Development of XPro1595 for the treatment of Alzheimer’s Disease
|
11 Feb, 2019 |
|
INmune Bio to Present at BIO CEO & Investor Conference
|
06 Feb, 2019 |
|
INmune Bio Inc. Announces Closing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol “INMB”
|
04 Feb, 2019 |
|
INmune Bio, Inc. Announces Pricing of Initial Public Offering
|
15 Jan, 2019 |
